Medicine details

ImageMaxsulin R 100  IU
NameMaxsulin R 100 IU
DosageInjection
Generic NameRegular or soluble human insulin
Classes Antidiabetic Agent
Diseases
CompanyIncepta Pharmaceuticals Ltd.

Drug Package Details

Strength100 IU/10 ml
Storage Condition
Origin CountryBangladesh
Commercial Pack1
Price per pack415.00
Cost per pack365.20
Package unit100 IU vial
Price per unit415.00
Cost per unit365.20
Discount0
Coupon
Remarks

Regular or soluble human insulin

Insulin is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria. Insulin's main function is to regulate glucose metabolism. Insulin reduces blood glucose levels by boosting skeletal muscle and adipose glucose absorption and blocking hepatic glucose synthesis. Insulins suppress lipolysis, proteolysis, and gluconeogenesis while boosting protein synthesis and fat conversion.

Regular or soluble human insulin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. Regular or soluble human insulin may be administered intravenously under proper medical supervision in a clinical setting for glycemic control.

  • Regular Insulin is usually taken twice or thrice a day, before meals. The dosage and timing of Regular Insulin should be individualized and determined by the physician in accordance with the patient's needs. A meal should be taken within 30 minutes of administering the Regular Insulin injection.
  • The average range of total daily insulin requirement for maintenance therapy in insulin-treated patients without severe insulin resistance lies between 0.5 and 1.0 unit/kg/day. However, in pre pubertal children it usually varies from 0.7 to 1.0 unit/kg/day, but can be much lower during the period of partial remission. In situations of insulin resistance, e.g., during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for type 2 diabetes patients are often lower, e.g., 0.2 to 0.4 units/kg/day. 
  • Insulin should not be used after the printed expiration date.
  • Do not mix regular soluble insulin with other insulins, as there are no data to support such use. 
  • Hypoglycemia
  • Hypoglycemia is one of the most frequent adverse events experienced by insulin users. Symptoms of mild to moderate hypoglycemia may occur suddenly and can include: • sweating • dizziness • palpitation • tremor • hunger • restlessness • tingling in the hands, feet, lips, or tongue • lightheadedness • drowsiness • sleep disturbances • anxiety • blurred vision • slurred speech • depressed mood • irritability • abnormal behavior 
  • Hypokalemia
  • Lipodystrophy
  • Allergy
  • Weight Gain 
  • Peripheral Edema

 

  • Any insulin change should be done with caution and only under medical supervision. Changes in insulin strength, manufacturer, type (e.g., regular, NPH, analog), species, or method of administration may necessitate a dosage adjustment.
  • Each milliliter of regular human insulin contains 500 units of insulin. The dosage must be measured with extreme caution because an accidental overdose can result in serious adverse reactions or life-threatening hypoglycemia.
  • Dosing Confusion/Dosing Errors Medication errors associated with Regular Human insulin have occurred and resulted in patients experiencing hyperglycemia, hypoglycemia or death. The majority of errors occurred due to errors in dispensing, prescribing or administration. Attention to the following details may prevent: 
    • Dispensing errors
    • Prescribing errors
    • Administration errors
  • Hypoglycemia: Hypoglycemia is the most common adverse reaction of all insulin therapies, including Regular Human insulin. Severe hypoglycemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or death. Severe hypoglycemia requiring the assistance of another person and/or parenteral glucose infusion or glucagon administration has been observed in clinical trials with insulin, including trials with Regular Human insulin. 
  • Hyperglycemia, Diabetic Ketoacidosis, and Hyperosmolar Non-Ketotic Syndrome: Hyperglycemia, diabetic ketoacidosis, or hyperosmolar coma may develop if the patient takes less Insulin than needed to control blood glucose levels. This could be due to increases in insulin demand during illness or infection, neglect of diet, omission or improper administration of prescribed insulin doses or use of drugs that affect glucose metabolism or insulin sensitivity. Early signs of diabetic ketoacidosis include glycosuria and ketonuria. Polydipsia, polyuria, loss of appetite, fatigue, dry skin, abdominal pain, nausea and vomiting and compensatory tachypnea come on gradually, usually over a period of some hours or days, in conjunction with hyperglycemia and ketonemia. Severe sustained hyperglycemia may result in hyperosmolar coma or death.
  • Hypokalemia: Insulin stimulates potassium movement into the cells, possibly leading to hypokalemia, that left untreated may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations). 
  • Hypersensitivity and Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products.
  • Renal or Hepatic Impairment: Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment.

Contraindication

Contraindicated in patients hypersensitive to Regular or soluble human insulin or any of its excipients. 

Contraindicated during Hypoglycemia.